Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1994 2
1997 2
1998 1
1999 1
2001 1
2003 1
2004 3
2005 4
2006 1
2007 3
2009 5
2010 2
2011 2
2012 1
2013 3
2014 1
2015 4
2016 3
2017 3
2018 2
2019 3
2020 7
2021 9
2022 7
2023 10
2024 8
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Explainable time-to-progression predictions in multiple sclerosis.
D'hondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, Havrdova EK, Lugaresi A, Weinstock-Guttman B, Mrabet S, Lalive P, Kermode AG, Ozakbas S, Patti F, Prat A, Tomassini V, Roos I, Alroughani R, Gerlach O, Khoury SJ, van Pesch V, Sá MJ, Prevost J, Spitaleri D, McCombe P, Solaro C, van der Walt A, Butzkueven H, Laureys G, Sánchez-Menoyo JL, de Gans K, Al-Asmi A, Deri N, Csepany T, Al-Harbi T, Carroll WM, Rozsa C, Singhal B, Hardy TA, Ramanathan S, Peeters L, Vens C; MSBase Study Group. D'hondt R, et al. Among authors: csepany t. Comput Methods Programs Biomed. 2025 May;263:108624. doi: 10.1016/j.cmpb.2025.108624. Epub 2025 Feb 6. Comput Methods Programs Biomed. 2025. PMID: 39965473
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group; Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C. Müller J, et al. Among authors: csepany t. JAMA Neurol. 2025 Jun 1;82(6):614-625. doi: 10.1001/jamaneurol.2025.0495. JAMA Neurol. 2025. PMID: 40227706
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M; for MSBase. Siriratnam P, et al. Among authors: csepany t. Neurology. 2024 Dec 24;103(12):e209940. doi: 10.1212/WNL.0000000000209940. Epub 2024 Nov 19. Neurology. 2024. PMID: 39561307
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Yamout B, Altintas A, Gerlach O, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Hughes S, Sa MJ, Solaro C, Kappos L, Hodgkinson S, Slee M, Granella F, de Gans K, McCombe PA, Ampapa R, van der Walt A, Butzkueven H, Sánchez-Menoyo JL, Vucic S, Laureys G, Sidhom Y, Gouider R, Castillo-Trivino T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Al-Harbi TM, Csepany T, Sempere AP, Treviño Frenk I, Stuart EA, Kalincik T. Diouf I, et al. Among authors: csepany t. J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):1004-1011. doi: 10.1136/jnnp-2023-331499. Epub 2023 Jul 6. J Neurol Neurosurg Psychiatry. 2023. PMID: 37414534 Clinical Trial.
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
Cortese M, Peng X, Edan G, Freedman MS, Hartung HP, Montalban X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Bjornevik K; BENEFIT Study Group. Cortese M, et al. Neurology. 2025 Aug 12;105(3):e213905. doi: 10.1212/WNL.0000000000213905. Epub 2025 Jul 17. Neurology. 2025. PMID: 40674673 Clinical Trial.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. Among authors: csepany t. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.
Shipley J, Beadnall HN, Sanfilippo PG, Yeh WZ, Horakova D, Havrdova EK, Hradilek P, Kalincik T, Roos I, Prat A, Girard M, Rous Z, Pavelek Z, Gerlach OHH, Lechner-Scott J, Alroughani R, Ozakbas S, Peterka M, Buzzard K, Skibina OG, Maimone D, Foschi M, Surcinelli A, Karabudak R, Spitaleri DLA, Lugaresi A, Tomassini V, Gouider R, Mrabet S, Ferrando BR, Hodgkinson S, Štourac P, Guimarães J, John NA, Macdonell RAL, Meca-Lallana JE, Butzkueven H, van der Walt A, Jokubaitis VG; MSBase Investigator Group. Shipley J, et al. JAMA Netw Open. 2025 Sep 2;8(9):e2531581. doi: 10.1001/jamanetworkopen.2025.31581. JAMA Netw Open. 2025. PMID: 40952740 Free PMC article.
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
Siriratnam P, Huda S, Van der Walt A, Sanfilippo P, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello C, Laureys G, Patti F, Horakova D, Foschi M, Boz C, McCombe P, Turkoglu R, Roos I, Lechner-Scott J, Kalincik T, Jokubaitis V, Butzkueven H, Monif M. Siriratnam P, et al. Among authors: csepany t. J Neurol. 2025 Apr 14;272(5):339. doi: 10.1007/s00415-025-13064-6. J Neurol. 2025. PMID: 40227344 Free PMC article.
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, Monif M; MSBASE study group. Siriratnam P, et al. Among authors: csepany t. J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):361-369. doi: 10.1136/jnnp-2024-334090. J Neurol Neurosurg Psychiatry. 2025. PMID: 39231582
92 results